

## —Inflation Reduction Act Research Series—

# Jardiance: Medicare Enrollee Use and Spending

This Fact Sheet provides information on **Jardiance**, one of the 10 drugs selected for the first cycle of Medicare drug price negotiations. Jardiance (active ingredient empagliflozin) is a small molecule drug used to treat diabetes and heart failure. These conditions are prevalent among the Medicare population, with about 28 percent of Medicare enrollees diagnosed with diabetes and 15 percent diagnosed with heart failure.

- Between 2018 and 2022, average annual total Part D spending per enrollee taking Jardiance (i.e., the total amount, including Medicare, plan, and enrollee payments, spent on Jardiance per person) increased by 45 percent (from \$3,063 to \$4,430).
- From 2018 through 2022, the average annual out-of-pocket spending per enrollee increased by 13 percent (from \$256 to \$290).

Table 1 presents data on utilization and spending for Jardiance among Part D enrollees. About 1.3 million Part D enrollees filled prescriptions for Jardiance in 2022. Relative to the total Part D population, a greater share of Jardiance users were men (55 percent vs. 44 percent), ages 74 or younger (73 percent vs. 63 percent), Black non-Latinos (14 percent vs. 11 percent), and Latinos (13 percent vs. 10 percent).

**Table 1. Medicare Part D Use and Spending on Jardiance, Calendar Year (CY) 2022**

	Total Enrollees	LIS Enrollees <sup>a</sup>	Non-LIS Enrollees
<b>Number of Part D Enrollees</b>	53,063,000	14,957,000	38,106,000
<b>Number of Enrollees Taking Jardiance</b>	1,321,000	562,000	759,000
<b>Share of Part D Enrollees Taking Jardiance</b>	3%	4%	2%
<b>Total Spending on Jardiance</b>			
<b>Total Spending</b>	\$5,852,233,000	\$2,696,085,000	\$3,156,148,000
<b>Average per Enrollee taking Jardiance</b>	\$4,430	\$4,800	\$4,156
<b>Enrollee Out-of-Pocket Spending on Jardiance</b>			
<b>Total OOP Spending</b>	\$383,346,000	\$11,029,000	\$372,318,000
<b>Average OOP per Enrollee taking Jardiance</b>	\$290	\$20	\$490

Notes: <sup>a</sup>For eligible Part D enrollees who meet income and asset requirements, the Low-Income Subsidy (LIS), also known as Extra Help, provides assistance with premiums, deductibles, and co-payments for covered Part D drugs.

*The Inflation Reduction Act was signed into law by President Biden in August 2022. Please see [here](#) for more information on how the law is reducing drug costs for Medicare beneficiaries.*

*Please see [here](#) for more information on Jardiance and the other drugs selected for the first cycle of Medicare drug price negotiation, cautions and limitations in interpretation and use of these estimates, and relevant citations.*